Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 6/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21151880 | 0.81 | KDM4E (0.41) | KDM4ETACR1CRBNDDB1 | |
| SCHEMBL21151775 | 0.77 | FPR2 (0.34) | — | |
| SCHEMBL21151182 | 0.72 | TACR1 (0.47) | ALDH1A1KDM4ETACR1HIF1A | |
| SCHEMBL21151912 | 0.67 | USP2 (0.47) | KDM4ECRBNDDB1 | |
| SCHEMBL23288812 | 0.67 | CTSD (0.45) | KDM4ECRBNDDB1 | |
| SCHEMBL31537333 | 0.66 | CTSD (0.44) | KDM4ECRBNDDB1 | |
| SCHEMBL29889238 | 0.65 | CRBN (0.59) | GAAHTTALDH1A1KDM4ECRBN | |
| SCHEMBL23288829 | 0.64 | MAPK1 (0.45) | KDM4ETACR1 | |
| SCHEMBL7099931 | 0.64 | CRBN (0.40) | GAAHTTALDH1A1TACR1ITGB3 | |
| SCHEMBL31706681 | 0.62 | CYP1A2 (0.46) | GAAHTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | GAA 553/4885HTT 2016/4885ALDH1A1 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.